摘要
随着我国人口老龄化社会的到来以及人们生活方式的改变,年龄相关性眼病、代谢相关性眼病、高度近视引发的眼底病变凸显,成为我国当前主要的致盲眼病。目前,手术治疗仍是白内障唯一的治疗手段,但白内障手术是有创治疗方法。我国老龄化人口的快速增加对年龄相关性白内障的预防以及延缓早中期白内障的进展速度也提出了挑战。白内障的发病机制包括晶状体蛋白质变性、氧化应激及晶状体上皮细胞凋亡,这些发病机制为白内障治疗药物研发提供了治疗靶点。虽然迄今为止尚无经过证实有效的白内障治疗药物,但在眼科工作者与药学研究者的共同努力下,我国的白内障药物研究仍取得了巨大进步。研发白内障治疗药物对于白内障患者选择无创治疗方式、避免手术的创伤及并发症、扩大白内障早期治疗的机会以及降低医疗成本有重要意义。我们应该在现有成绩的基础上面对挑战,继续努力,重视白内障防治药物的研发,从而进一步降低白内障的致盲率。
With the aging of the population and changes of people's lifestyle,age-related eye disease,metabolic-related eye disease and fundus lesions caused by high myopia become the main causes of blindness in China.Up to now,the only therapy for age-related cataract is still surgery to remove and replace the opacified lens.However,surgery for cataract is an invasive therapy,and the rapid increase of aging population and rising incidence of cataract put forward a huge challenge for the prevention of cataract and retarding the progress of cataract.Cataract pathogenesis includes protein crystallization partially unfolding and subsequently aggravating,oxidative stress and lens epithelial cells apoptosis,and these provide treatable targets for cataract drugs.Based on these pathogenesis,scientists have been looking for possible treatment drugs.Although so far there is no proven effective drugs,ophthalmologists and pharmacists have made an exciting progress and novel discovery in China.Pursuing a pharmacologic treatment for cataract is of important significance for selecting non-invasive therapies based on patient's will,avoiding surgical complications,expanding access to cataract treatment and reducing healthcare costs.We should keep making effort on research and development of drug for cataract,in order to further reduce the blindness rate of cataract.
作者
王延东
Wang Yandong(Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangzhou 510060,China)
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2020年第12期1001-1003,共3页
Chinese Journal Of Experimental Ophthalmology
基金
广东省自然科学基金项目(2016A030313294)。
关键词
白内障/治疗
药物研发
致盲率
Cataracts/therapy
Drug discovery
Blindness rate
